Published in Nat Biotechnol on April 17, 2005
Precise genome modification in the crop species Zea mays using zinc-finger nucleases. Nature (2009) 4.71
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 3.80
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25
PD-1 signaling in primary T cells. Immunol Rev (2009) 2.66
A synthetic sex ratio distortion system for the control of the human malaria mosquito. Nat Commun (2014) 1.95
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
A second look at cellular mRNA sequences said to function as internal ribosome entry sites. Nucleic Acids Res (2005) 1.93
Treatment of human disease by adeno-associated viral gene transfer. Hum Genet (2006) 1.84
Inhibition of 2A-mediated 'cleavage' of certain artificial polyproteins bearing N-terminal signal sequences. Biotechnol J (2010) 1.57
Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther (2011) 1.41
Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J (2006) 1.38
Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame. Cell Res (2009) 1.29
Marking embryonic stem cells with a 2A self-cleaving peptide: a NKX2-5 emerald GFP BAC reporter. PLoS One (2008) 1.22
Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines. PLoS One (2011) 1.18
Use of the 2A peptide for generation of multi-transgenic pigs through a single round of nuclear transfer. PLoS One (2011) 1.10
Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol (2011) 1.07
Development of synthetic selfish elements based on modular nucleases in Drosophila melanogaster. Nucleic Acids Res (2014) 1.05
Generation of stable Drosophila cell lines using multicistronic vectors. Sci Rep (2011) 1.03
Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets (2011) 0.95
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem (2015) 0.95
Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun (2009) 0.94
Phage display mediated immuno-PCR. Nucleic Acids Res (2006) 0.94
Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One (2014) 0.94
Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One (2012) 0.94
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. J Clin Invest (2010) 0.93
Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther (2010) 0.93
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Bicistronic lentiviruses containing a viral 2A cleavage sequence reliably co-express two proteins and restore vision to an animal model of LCA1. PLoS One (2011) 0.93
Protein coexpression using FMDV 2A: effect of "linker" residues. Biomed Res Int (2013) 0.92
Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol (2007) 0.92
Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol (2015) 0.91
Genetic manipulation in pigs. Curr Opin Organ Transplant (2009) 0.90
Mammalian interspecies substitution of immune modulatory alleles by genome editing. Sci Rep (2016) 0.89
AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med (2012) 0.89
Versatile co-expression of graft-protective proteins using 2A-linked cassettes. Xenotransplantation (2011) 0.89
AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther (2012) 0.89
Multimodal protein constructs for herbivore insect control. Toxins (Basel) (2012) 0.89
AAV Vectors Vaccines Against Infectious Diseases. Front Immunol (2014) 0.88
Tools for Anopheles gambiae Transgenesis. G3 (Bethesda) (2015) 0.88
Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications. BMC Biotechnol (2013) 0.88
Light-inducible genetic engineering and control of non-homologous end-joining in industrial eukaryotic microorganisms: LML 3.0 and OFN 1.0. Sci Rep (2016) 0.87
AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog (2015) 0.87
AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther (2010) 0.87
Cdc37 regulates Ryk signaling by stabilizing the cleaved Ryk intracellular domain. J Biol Chem (2009) 0.87
A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clin Vaccine Immunol (2009) 0.87
Comparison of internal ribosome entry site (IRES) and Furin-2A (F2A) for monoclonal antibody expression level and quality in CHO cells. PLoS One (2013) 0.86
Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. Mol Ther Methods Clin Dev (2015) 0.86
Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. Hum Gene Ther (2011) 0.86
Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines (2013) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Enhanced genetic tools for engineering multigene traits into green algae. PLoS One (2014) 0.85
Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One (2011) 0.84
Gamma-retroviral vectors enveloped with an antibody and an engineered fusogenic protein achieved antigen-specific targeting. Biotechnol Bioeng (2008) 0.84
The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches. Curr Gene Ther (2013) 0.83
Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. PLoS One (2013) 0.83
TEV protease-facilitated stoichiometric delivery of multiple genes using a single expression vector. Protein Sci (2010) 0.83
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia (2014) 0.82
A predictive biophysical model of translational coupling to coordinate and control protein expression in bacterial operons. Nucleic Acids Res (2015) 0.82
Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production. Nucleic Acids Res (2009) 0.82
Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS (2015) 0.82
Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS (2014) 0.82
Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. MAbs (2015) 0.81
Repeated integration of antibody genes into a pre-selected chromosomal locus of CHO cells using an accumulative site-specific gene integration system. Cytotechnology (2011) 0.81
Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters. PLoS One (2012) 0.81
Simultaneous expression of multiple proteins under a single promoter in Caenorhabditis elegans via a versatile 2A-based toolkit. Genetics (2013) 0.81
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin Dev (2016) 0.80
Expression analysis of combinatorial genes using a bi-cistronic T2A expression system in porcine fibroblasts. PLoS One (2013) 0.80
2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice. Mol Ther (2011) 0.80
Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One (2012) 0.80
Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release (2016) 0.80
Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge. Gene Ther (2010) 0.80
Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease. ACS Chem Biol (2014) 0.80
Production and characterization of chimeric monoclonal antibodies against Burkholderia pseudomallei and B. mallei using the DHFR expression system. PLoS One (2011) 0.79
Constitutive Gs activation using a single-construct tetracycline-inducible expression system in embryonic stem cells and mice. Stem Cell Res Ther (2011) 0.79
Therapeutic antibody gene transfer. Nat Biotechnol (2005) 0.79
Immunotherapeutic organoids: a new approach to cancer treatment. Biomatter (2013) 0.79
Engineering humoral immunity as prophylaxis or therapy. Curr Opin Immunol (2015) 0.79
Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect. Hum Gene Ther (2012) 0.79
High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing. Mol Ther Methods Clin Dev (2015) 0.78
Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm Res (2009) 0.78
Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Ther (2014) 0.78
Use of lentiviral vectors to deliver and express bicistronic transgenes in developing chicken embryos. Methods (2013) 0.78
RANGE: Gene Transfer of Reversibly Controlled Polycistronic Genes. Mol Ther Nucleic Acids (2013) 0.78
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG. PLoS One (2016) 0.77
Passive immunization against HIV/AIDS by antibody gene transfer. Viruses (2014) 0.77
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev (2017) 0.77
Automated pipeline for rapid production and screening of HIV-specific monoclonal antibodies using pichia pastoris. Biotechnol Bioeng (2015) 0.76
Generation of Kcnma1fl-tdTomato, a conditional deletion of the BK channel α subunit in mouse. Physiol Rep (2015) 0.76
Improved methods of AAV-mediated gene targeting for human cell lines using ribosome-skipping 2A peptide. Nucleic Acids Res (2015) 0.76
Immunogenomic engineering of a plug-and-(dis)play hybridoma platform. Nat Commun (2016) 0.76
Novel Reporter for Faithful Monitoring of ERK2 Dynamics in Living Cells and Model Organisms. PLoS One (2015) 0.76
High-throughput sorting of the highest producing cell via a transiently protein-anchored system. PLoS One (2014) 0.76
2A self-cleaving peptide-based multi-gene expression system in the silkworm Bombyx mori. Sci Rep (2015) 0.76
Gene-based passive antibody protection from HIV. Nat Biotechnol (2012) 0.76
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
Immunotherapy made more accessible? CMAJ (2005) 0.75
Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice. Sci Rep (2017) 0.75
Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A. Medicine (Baltimore) (2015) 0.75
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem (2005) 3.38
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med (2003) 2.35
Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol (2002) 1.77
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res (2006) 1.60
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 1.60
An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther (2007) 1.26
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol (2007) 1.19
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res (2007) 1.18
Human immunodeficiency virus-1 Nef expression induces intracellular accumulation of multivesicular bodies and major histocompatibility complex class II complexes: potential role of phosphatidylinositol 3-kinase. Mol Biol Cell (2003) 1.18
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother (2008) 1.09
GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol (2006) 1.08
Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. J Biol Chem (2003) 1.08
Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res (2008) 1.04
Febuxostat methanol solvate. Acta Crystallogr Sect E Struct Rep Online (2011) 0.96
Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opin Drug Saf (2002) 0.95
The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. BMC Syst Biol (2013) 0.92
Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother (2006) 0.91
Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol (2007) 0.90
Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hum Gene Ther (2002) 0.90
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother (2006) 0.89
Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther (2004) 0.89
Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol Immunother (2010) 0.87
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clin Immunol (2009) 0.87
Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. J Gene Med (2003) 0.85
Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models. Clin Cancer Res (2005) 0.84
Combination of the 2A/furin technology with an animal component free cell line development platform process. Appl Microbiol Biotechnol (2010) 0.84
GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother (2007) 0.83
Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Mol Ther (2007) 0.83
Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res (2005) 0.82
Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Exp Hematol (2008) 0.82
Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J Gene Med (2004) 0.81
AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Ther (2006) 0.81
Tolerance induction to self antigens by peripheral dendritic cells. Eur J Immunol (2002) 0.81
Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clin Immunol (2013) 0.79
Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy. Clin Cancer Res (2008) 0.79
Endoscopic ultrasonography for the diagnosis and selecting treatment of esophageal leiomyoma. J Gastroenterol Hepatol (2012) 0.78
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J Virol (2009) 0.78
Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice. Hum Gene Ther (2009) 0.77
Ultrasonographic characteristics of urolithiasis in children exposed to melamine-tainted powdered formula. World J Pediatr (2009) 0.77
Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther (2004) 0.77
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun (2016) 0.77
Moxifloxacinium chloride monohydrate. Acta Crystallogr Sect E Struct Rep Online (2011) 0.75
Marbofloxacin. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Eprosartan mesylate, an angiotensin II receptor antagonist. Acta Crystallogr Sect E Struct Rep Online (2011) 0.75
Quetiapine N-oxide-fumaric acid (2/1). Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Rapid generation of high-level antibodies in vitro and in vivo. Discov Med (2005) 0.75